Troglitazone

Troglitazone

Clinical data
ATC code	A10BG01 (WHO)
Pharmacokinetic data
Elimination half-life	16-34 hours
Identifiers
IUPAC name 5-(4-((6-hydroxy-2,5,7,8- tetramethylchroman-2-yl-methoxy) benzyl)-2,4-thiazolidinedione)
CAS Number	97322-87-7
PubChem CID	5591
DrugBank	APRD00488
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C24H27NO5S
Molar mass	441.541 g/mol

WikiDoc Resources for Troglitazone
Articles
Most recent articles on Troglitazone Most cited articles on Troglitazone Review articles on Troglitazone Articles on Troglitazone in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Troglitazone Images of Troglitazone Photos of Troglitazone Podcasts & MP3s on Troglitazone Videos on Troglitazone
Evidence Based Medicine
Cochrane Collaboration on Troglitazone Bandolier on Troglitazone TRIP on Troglitazone
Clinical Trials
Ongoing Trials on Troglitazone at Clinical Trials.gov Trial results on Troglitazone Clinical Trials on Troglitazone at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Troglitazone NICE Guidance on Troglitazone NHS PRODIGY Guidance FDA on Troglitazone CDC on Troglitazone
Books
Books on Troglitazone
News
Troglitazone in the news Be alerted to news on Troglitazone News trends on Troglitazone
Commentary
Blogs on Troglitazone
Definitions
Definitions of Troglitazone
Patient Resources / Community
Patient resources on Troglitazone Discussion groups on Troglitazone Patient Handouts on Troglitazone Directions to Hospitals Treating Troglitazone Risk calculators and risk factors for Troglitazone
Healthcare Provider Resources
Symptoms of Troglitazone Causes & Risk Factors for Troglitazone Diagnostic studies for Troglitazone Treatment of Troglitazone
Continuing Medical Education (CME)
CME Programs on Troglitazone
International
Troglitazone en Espanol Troglitazone en Francais
Business
Troglitazone in the Marketplace Patents on Troglitazone
Experimental / Informatics
List of terms related to Troglitazone

Troglitazone (Rezulin®, Resulin® or Romozin®) is a member of the drug class of the thiazolidinediones. It was introduced in the late 1990s but turned out to be associated with an idiosyncratic reaction leading to drug-induced hepatitis. It was withdrawn from the USA market on 21 March 2000, and from other markets soon afterwards.

Troglitazone, like the other thiazolidinediones (pioglitazone and rosiglitazone), works by activating PPARs (peroxisome proliferator-activated receptors). Troglitazone is a ligand to both PPARα and - more strongly - PPARγ. Troglitazone also contains an α-tocopheroyl moiety, potentially giving it vitamin E-like activity in addition to its PPAR activation. It has been shown (Aljada et al) to reduce inflammation: troglitazone use was associated with a decrease of nuclear factor kappa-B (NFκB) and a concomitant increase in its inhibitor (IκB). NFκB is an important cellular transcription regulator for the immune response.

References

• Aljada A., Garg R., Ghanim H., Mohanty P., Hamouda W., Assian E., Dandona P.: Nuclear factor-κB suppressive and inhibitor-κB stimulatory effects of troglitazone in obese patients with type 2 diabetes: evidence of an antiinflammatory action? J. Clin. Endocrinol. Metab. 2001, 86, 3250-6. Fulltext. PMID 11443197.

See also

• Thiazolidinedione
• PPAR

External links

• Diabetes Monitor article on troglitazone
• RxList article on troglitazone
• FDA Recall FDA Recall Announcement

Template:WikiDoc Sources